Imagion Biosystems (ASX:IBX) is preparing for Phase 2

Imagion Biosystems (ASX: IBX) is the company behind MagSense, a revolutionary imaging agent. The company has just made an IND submission to the US FDA and plans to take MagSense into a Phase 2 clinical trial for HER2+ breast cancer once an answer from the regulator is received and this could be as early as Q1 in 2026. A $2bn TAM awaits The market for cancer diagnostics is a US$100bn market. […]
Green360 Technologies

Green360 Technologies (ASX:GT3): In the low-carbon cement market with a big headstart

Green360 Technologies (ASX:GT3) is a building materials company. It is already a producer of kaolin but is also developing low-carbon and low-cost concrete technology. Already making money The company owns Australia’s only wet processing Kaolin Operation (Pittong in Victoria) where it is already generating revenue (>$25m over FY24 & FY25) from by selling several products […]
Register for the Conference